XenoPort Shares Plunge On Negative Phase IIb Study
Shares of XenoPort (NASDAQ: XNPT) have plunged on negative Phase IIb study.
The Santa Clara, California-based developer, along with GlaxoSmithKline (NYSE: GSK), said that a Phase IIb study for gabapentin enacarbil failed to “demonstrate a statistically significant improvement compared to placebo as a prophylactic treatment for migraine headaches."
XNPT’s shares plunged 27.28% to $6.45 at 9:45 am EDT.
Read more from Benzinga's Company news.
Learn how to find the best stocks to trade each day in our 70 page E-Book and 90 minute online video for free.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.